Treatment of Fractures and Non- Unions in Children with Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 405

References
[1] Sillence D. Osteogenesis imperfecta: an expanding panorama
of variants. Clin Orthop Relat Res 1981;159:11-25.
[2] Sillence DO, Rimoin DL. Classiication of osteogenesis imper-
fect. Lancet 1978;1(8072):1041-2.
[3] Sillence DO, Senn A, Danks DM. Genetic heterogeneity in
osteogenesis imperfecta. J Med Genet 1979;16(2):101-16.
[4] Paterson CR, McAllion S, Miller R. Osteogenesis imperfecta
with dominant inheritance and normal sclerae. J Bone Joint
Surg Br 1983;65(1):35-9.
[5] Cheung MS, Glorieux FH. Osteogenesis imperfecta: update
on presentation and management. Rev Endocr Metab Disord
2008;9(2):153-60.
[6] Lee DY, Cho TJ, Choi IH, Chung CY, Yoo WJ, Kim JH, et al.
Clinical and radiological manifestations of osteogenesis imper-
fecta type V. J Korean Med Sci 2006;21(4):709-14.
[7] Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R,
Roughley P, et al. Type V osteogenesis imperfecta: a new form
of brittle bone disease. J Bone Miner Res 2000;15(9):1650-8.
[8] Fassier AM, Rauch F, Aarabi M, Janelle C, Fassier F. Radial
head dislocation and subluxation in osteogenesis imperfecta.
J Bone Joint Surg Am 2007;89(12):2694-704.
[9] Hui PK, Tung JY, Lam WW, Chau MT. Osteogenesis imperfecta
type V. Skeletal Radiol 2011;40(12):1609-33.
[10] Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ,
Travers R. Osteogenesis imperfecta type VI: a form of brittle
bone disease with a mineralization defect. J Bone Miner Res
2002;17(1):30-8.
[11] Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L,
et al. Osteogenesis imperfecta type VII: an autosomal recessive
form of brittle bone disease. Bone 2002;31(1):12-18.
[12] Martin E, Shapiro JR. Osteogenesis imperfecta:epidemiology
and pathophysiology. Curr Osteoporos Rep 2007;5(3):91-7.
[13] Forlino A, Cabral WA, Barnes AM, Marini JC. New per-
spectives on osteogenesis imperfecta. Nat Rev Endocrinol
2011;7(9):540-57.
[14] Shapiro F. Consequences of an osteogenesis imperfecta diagnosis
for survival and ambulation. J Pediatr Orthop 1985;5(4):456-62.
[15] Constantinou CD, Pack M, Young SB, Prockop DJ. Phenotypic
heterogeneity in osteogenesis imperfecta: the mildly affected
mother of a proband with a lethal variant has the same mutation
substituting cysteine for alpha 1-glycine 904 in a type I procolla-
gen gene (COL1A1). Am J Hum Genet 1990;47(4):670-9.
[16] Plotkin H. Two questions about osteogenesis imperfecta.
J Pediatr Orthop 2006;26(1):148-9.
[17] Semler O, Cheung MS, Glorieux FH, Rauch F. Wormian bones
in osteogenesis imperfecta: correlation to clinical indings and
genotype. Am J Med Genet A 2010;152A(7):1681-7.
[18] Cundy T. Recent advances in osteogenesis imperfecta. Calcif
Tissue Int 2012;90(6):439-49.
[19] Moore MS, Minch CM, Kruse RW, Harcke HT, Jacobson L,
Taylor A. The role of dual energy x-ray absorptiometry in aid-
ing the diagnosis of pediatric osteogenesis imperfecta. Am J
Orthop (Belle Mead NJ) 1998;27(12):797-801.
[20] Zionts LE, Nash JP, Rude R, Ross T, Stott NS. Bone mineral
density in children with mild osteogenesis imperfecta. J Bone
Joint Surg Br 1995;77(1):143-7.
[21] Huang RP, Ambrose CG, Sullivan E, Haynes RJ. Functional sig-
niicance of bone density measurements in children with osteo-
genesis imperfecta. J Bone Joint Surg Am 2006;88(6):1324-30.
[22] Byers PH, Krakow D, Nunes ME, Pepin M. Genetic evalua-
tion of suspected osteogenesis imperfecta (OI). Genet Med
2006;8(6):383-8.
[23] Steiner RD, Pepin MG, Byers PH. Osteogenesis imperfecta.
1993. Seattle, WA: University of Washington.

[24] Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE,
Chernoff EJ, et al. Controlled trial of pamidronate in children
with types III and IV osteogenesis imperfecta conirms verte-
bral gains but not short-term functional improvement. J Bone
Miner Res 2005;20(6):977-86.
[25] Bajpai A, Kabra M, Gupta N, Sharda S, Ghosh M. Intravenous
pamidronate therapy in osteogenesis imperfecta: response to
treatment and factors inluencing outcome. J Pediatr Orthop
2007;27(2):225-7.
[26] Jakubowska-Pietkiewicz E, Chlebna-Sokol D. New trends in
the treatment of osteogenesis imperfecta type III - own experi-
ence. Ortop Traumatol Rehabil 2008;10(6):593-601.
[27] Lowing K, Astrom E, Oscarsson KA, Soderhall S, Eliasson AC.
Effect of intravenous pamidronate therapy on everyday activi-
ties in children with osteogenesis imperfecta. Acta Paediatr
2007;96(8):1180-3.
[28] Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J,
Travers R, et al. Pamidronate treatment of severe osteogenesis
imperfecta in children under 3 years of age. J Clin Endocrinol
Metab 2000;85(5):1846-50.
[29] Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in chil-
dren with osteogenesis imperfecta. J Pediatr Endocrinol Metab
2010;23(1-2):73-80.
[30] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G,
Travers R. Cyclic administration of pamidronate in chil-
dren with severe osteogenesis imperfecta. N Engl J Med
1998;339(14):947-52.
[31] Glorieux FH. Experience with bisphosphonates in osteogenesis
imperfecta. Pediatrics 2007;119(Suppl 2):S163-5.
[32] Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intrave-
nous pamidronate on the bone tissue of children and adolescents
with osteogenesis imperfecta. J Clin Invest 2002;110(9):1293-9.
[33] Rauch F, Glorieux FH. Treatment of children with osteogenesis
imperfecta. Curr Osteoporos Rep 2006;4(4):159-64.
[34] Falvo KA, Root L, Bullough PG. Osteogenesis imperfecta:
clinical evaluation and management. J Bone Joint Surg Am
1974;56(4):783-93.
[35] King JD, Bobechko WP. Osteogenesis imperfecta. An ortho-
paedic description and surgical review. J Bone Joint Surg Br
1971;53(1):72-89.
[36] Mooreield Jr WG, Miller GR. Aftermath of osteogenesis
imperfecta: the disease in adulthood. J Bone Joint Surg Am
1980;62(1):113-9.
[37] Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M,
Pruijs H, et al. Skeletal effects and functional outcome
with olpadronate in children with osteogenesis imper-
fecta: a 2-year randomised placebo-controlled study. Lancet
2004;363(9419):1427-31.
[38] Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imper-
fecta type VI in childhood and adolescence: effects of cyclical
intravenous pamidronate treatment. Bone 2007;40(3):638-44.
[39] Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N.
Response to zolendronic acid in children with type III osteo-
genesis imperfecta. J Bone Miner Metab 2010;28(4):451-5.
[40] Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L,
et al. Intravenous neridronate in children with osteogenesis
imperfecta: a randomized controlled study. J Bone Miner Res
2005;20(5):758-63.
[41] Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D,
Browne R, et al. Impact of alendronate on quality of life in
children with osteogenesis imperfecta. J Pediatr Orthop
2005;25(6):786-91.
[42] Rauch F, Munns CF, Land C, Cheung M, Glorieux FH.
Risedronate in the treatment of mild pediatric osteogenesis
imperfecta: a randomized placebo-controlled study. J Bone
Miner Res 2009;24(7):1282-9.